Scarica l'app Stockscreener
23.18
0.09%
0.02
Dopo l'orario di chiusura:
23.20
0.02
+0.09%
Precedente Chiudi:
$23.16
Aprire:
$23.3
Volume 24 ore:
4.00M
Relative Volume:
1.45
Capitalizzazione di mercato:
$2.00B
Reddito:
$17.49M
Utile/perdita netta:
$-78.50M
Rapporto P/E:
-19.32
EPS:
-1.2
Flusso di cassa netto:
$-52.85M
1 W Prestazione:
-4.41%
1M Prestazione:
-10.95%
6M Prestazione:
+69.44%
1 anno Prestazione:
+99.31%
Intervallo 1D:
$22.92
$24.65
Intervallo di 1 settimana:
$22.39
$24.65
Portata 52W:
$9.71
$29.94
Liquidia Corp Stock (LQDA) Company Profile
Nome
Liquidia Corp
Settore
Industria
Telefono
919.328.4400
Indirizzo
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Confronta LQDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
23.18 | 1.96B | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-15 | Ripresa | Jefferies | Buy |
| 2025-05-19 | Downgrade | Oppenheimer | Perform → Underperform |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-16 | Iniziato | Raymond James | Outperform |
| 2024-06-25 | Iniziato | Oppenheimer | Perform |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2022-09-19 | Ripresa | Wedbush | Underperform |
| 2022-09-01 | Downgrade | Wedbush | Neutral → Underperform |
| 2022-07-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-05-31 | Iniziato | BTIG Research | Buy |
| 2022-05-26 | Iniziato | BofA Securities | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-05 | Iniziato | Wedbush | Outperform |
| 2018-08-20 | Iniziato | Jefferies | Buy |
| 2018-08-20 | Iniziato | Needham | Buy |
Mostra tutto
Liquidia Corp Borsa (LQDA) Ultime notizie
Applying sector rotation models to Liquidia CorporationTrend Reversal & Safe Entry Momentum Tips - newser.com
Liquidia CFO Kaseta sells $272k in shares - Investing.com
Will Liquidia Corporation stock attract more institutional investors2025 EndofYear Setup & Daily Risk Controlled Trade Plans - newser.com
Is Liquidia Corporation stock attractive for income investors2025 Institutional Moves & Detailed Earnings Play Strategies - newser.com
Is Liquidia Corporation (LT4) stock prepared for digital transition2025 Winners & Losers & Low Risk Entry Point Guides - newser.com
What’s the recovery path for long term holders of Liquidia CorporationJuly 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
How Liquidia Corporation stock performs in stagflationEarnings Miss & Real-Time Volume Analysis Alerts - newser.com
Will Liquidia Corporation rebound enough to break evenJuly 2025 Spike Watch & Daily Market Momentum Tracking - newser.com
What sentiment indicators say about Liquidia Corporation stockFed Meeting & Daily Risk Controlled Trade Plans - newser.com
Is Liquidia Corporation showing signs of accumulationFed Meeting & Technical Pattern Alert System - newser.com
Real time alert setup for Liquidia Corporation performanceQuarterly Trade Review & AI Based Buy and Sell Signals - newser.com
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - MSN
Liquidia Technologies (NASDAQ:LQDA) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Bank of America Securities Sticks to Their Buy Rating for Liquidia Technologies (LQDA) - The Globe and Mail
Liquidia Corporation’s volatility index tracking explained2025 Market Overview & Weekly High Return Opportunities - newser.com
BofA Adjusts Price Target on Liquidia to $37 From $35 - MarketScreener
Will Liquidia's (LQDA) R&D Day Reveal a Shift in Its Innovation Strategy? - simplywall.st
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 - The Manila Times
Liquidia Corporation Announces First Research & Development Day Focusing on Innovative Therapies for Pulmonary Hypertension - Quiver Quantitative
Oct. 28 R&D Day — Liquidia to present L606 sustained‑release and YUTREPIA clinical update; webcast - Stock Titan
Liquidia Corporation (LQDA) Stock Analysis: A Biotech Player With A 60% Upside Potential - DirectorsTalk Interviews
HC Wainwright Reaffirms Buy Rating for Liquidia Technologies (NASDAQ:LQDA) - MarketBeat
LQDA: HC Wainwright Reiterates Buy Rating with $35 PT | LQDA Sto - GuruFocus
What machine learning models say about Liquidia CorporationJuly 2025 Opening Moves & Stock Market Timing Techniques - newser.com
Can Liquidia Corporation (LT4) stock ride next bull market cycleJuly 2025 Macro Moves & High Accuracy Investment Signals - newser.com
Liquidia (LQDA): Evaluating Valuation After Positive Tyvaso Results Shift Pulmonary Treatment Landscape - simplywall.st
Liquidia Corporation Stock Analysis and ForecastVolatility Trading Techniques & Stocks to Buy Before Earnings Season - earlytimes.in
Analyzing drawdowns of Liquidia Corporation with statistical tools2025 Support & Resistance & Safe Entry Trade Signal Reports - newser.com
Combining machine learning predictions for Liquidia CorporationDividend Hike & Smart Money Movement Alerts - newser.com
Is Liquidia Corporation (LT4) stock a top dividend aristocrat candidateJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com
Will Liquidia Corporation stock outperform value stocksPortfolio Update Report & Free Expert Verified Stock Movement Alerts - newser.com
Will Liquidia Corporation (LT4) stock sustain uptrend momentumWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com
UTC, Liquidia Clash on Xarelto Patent Ruling’s Tyvaso Impact - Bloomberg Law News
3 Growth Companies With High Insider Ownership Seeing Up To 63% Revenue Growth - simplywall.st
Breaking PH-ILD Research: Liquidia's LIQ861 16-Week Trial Data to be Revealed at Major CHEST Conference - Stock Titan
Multi asset correlation models including Liquidia CorporationJuly 2025 Update & Fast Gain Stock Trading Tips - newser.com
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting - Yahoo Finance
Liquidia Corporation's (NASDAQ:LQDA) institutional investors lost 9.0% over the past week but have profited from longer-term gains - simplywall.st
Liquidia Technologies (NASDAQ:LQDA) Shares Gap UpWhat's Next? - MarketBeat
Liquidia Corporation (LQDA) Presents Strategic Overview at Well Fargo’s Annual Healthcare Conference 2025 - Yahoo Finance
Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares? - Yahoo Finance
Liquidia Technologies, Inc. (NASDAQ:LQDA) Receives $32.11 Average PT from Analysts - MarketBeat
Insider Selling: Liquidia Technologies (NASDAQ:LQDA) Director Sells 45,524 Shares of Stock - MarketBeat
Exit strategy if you’re trapped in Liquidia CorporationMarket Sentiment Report & Reliable Price Action Trade Plans - newser.com
Should you hold or exit Liquidia Corporation nowWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com
How to monitor Liquidia Corporation with trend dashboards2025 EndofYear Setup & High Accuracy Trade Alerts - newser.com
Liquidia Corp Azioni (LQDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Liquidia Corp Azioni (LQDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kaseta Michael | CFO and COO |
Oct 13 '25 |
Sale |
23.41 |
11,630 |
272,258 |
352,646 |
| Moomaw Scott | Chief Commercial Officer |
Oct 13 '25 |
Sale |
23.41 |
4,900 |
114,709 |
153,462 |
| Saggar Rajeev | Chief Medical Officer |
Oct 13 '25 |
Sale |
23.41 |
5,327 |
124,705 |
247,930 |
| Boyle Dana | Chief Accounting Officer |
Oct 13 '25 |
Sale |
23.41 |
1,238 |
28,982 |
185,411 |
| JEFFS ROGER | Chief Executive Officer |
Oct 13 '25 |
Sale |
23.41 |
20,261 |
474,310 |
1,032,973 |
| Adair Jason | Chief Business Officer |
Oct 13 '25 |
Sale |
23.41 |
3,670 |
85,915 |
175,690 |
| Krepp Sarah | Chief Human Resource Officer |
Oct 13 '25 |
Sale |
23.41 |
1,691 |
39,586 |
141,439 |
| SINGH RAMAN | Director |
Sep 15 '25 |
Option Exercise |
2.55 |
45,524 |
115,865 |
76,779 |
| SINGH RAMAN | Director |
Sep 15 '25 |
Sale |
25.81 |
45,524 |
1,174,974 |
31,255 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):